We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01328769
Recruitment Status : Completed
First Posted : April 5, 2011
Results First Posted : September 17, 2015
Last Update Posted : September 17, 2015
Information provided by (Responsible Party):
Paul N. Hopkins, University of Utah

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Basic Science
Condition: Hypertension
Interventions: Drug: Febuxostat
Drug: Placebo

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Febuxostat 80mg once daily
Placebo Matching placebo dose 80mg once daily

Participant Flow:   Overall Study
    Febuxostat   Placebo
STARTED   25   24 
COMPLETED   25   23 

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Febuxostat 80mg daily
Placebo Matching placebo dose 80mg once daily
Total Total of all reporting groups

Baseline Measures
   Febuxostat   Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 25   23   48 
[Units: Years]
Mean (Standard Deviation)
 50.6  (8.1)   48.6  (8.0)   49.6  (8.1) 
[Units: Participants]
Female   4   4   8 
Male   21   19   40 

  Outcome Measures

1.  Primary:   Change in Renal Plasma Flow in Response to Infused Angiotensin II   [ Time Frame: Baseline to 6 weeks ]

2.  Secondary:   Change in Endothelial Function   [ Time Frame: Baseline to 6 weeks ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Paul Hopkins
Organization: University of Utah
phone: 801-585-8139
e-mail: paul.hopkins@utah.edu

Responsible Party: Paul N. Hopkins, University of Utah
ClinicalTrials.gov Identifier: NCT01328769     History of Changes
Other Study ID Numbers: 42916
First Submitted: March 29, 2011
First Posted: April 5, 2011
Results First Submitted: July 7, 2015
Results First Posted: September 17, 2015
Last Update Posted: September 17, 2015